US Edition
Published • loading... • Updated
Zepbound’s growth fuels new employer coverage models
Summary by CDR – Chain Drug Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Zepbound’s growth fuels new employer coverage models
INDIANAPOLIS — The success of Eli Lilly’s blockbuster weight-loss drug Zepbound (tirzepatide) is fueling a surge of new access strategies, as employers, pharmacies, and digital health platforms work to help patients afford the rapidly expanding obesity treatment.At the core of this effort is Lilly’s newly launched Employer Connect platform, which enables employers to work with independent program administrators to provide access to obesity medic…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
